Medical News Feed
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Vinca alkaloids (cytotoxics). |
| Generic Name : | Vinblastine |
| Drug description : | Powder (in form of lyophilised plug) in vials. |
| Presentation : | Powder for injection, vinblastine sulphate 10 mg . |
| Indications : | For intravenous use. Current information suggests Velbe may be useful, either alone or in combination with other oncolytic drugs for the treatment of: Hodgkin's disease; non-Hodgkin's lymphoma; carcinoma of the breast; methotrexate-resistant choriocarcinoma; renal cell carcinoma; testicular teratoma and seminoma; histiocytosis X. Other neoplasms occasionally show a marked response to Velbe, but less frequently than the more susceptible conditions listed above. |
| Adult Dosage : | For intravenous use only; fatal if given intrathecally. Should be administered only by individuals experienced in vinblastine administration. Recommended dose is 6mg/m2 usually administered no more frequently than every seven days. frequently than every seven days. For testicular tumours, the dosage may be increased to 0.2mg/ kg administered on each of two consecutive days every three weeks. Refer to Summary of Product Characteristics. |
| Child Dosage : | For intravenous use only; fatal if given intrathecally. Dose, as for adults. |
| Contra Indications : | Intrathecal administration. Should not be used in patients with leucopenia (unless a result of the disease being treated) or bacterial infection. Pregnancy, lactation. |
| Special Precautions : | Refer to Summary of Product Characteristics. |
| Interactions : | Refer to Summary of Product Characteristics. |
| Adverse Reactions : | Leucopenia is the most common adverse effect (usually the dose- limiting factor). After high doses, most commonly, constipation, abdominal pain, ileus and myalgia. Refer to Summary of Product Characteristics. |
| Manufacturer : | Lilly |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org